PMID- 24828136
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140622
LR  - 20240330
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 5
IP  - 1
DP  - 2014 Jun
TI  - Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues.
PG  - 65-72
LID - 10.1007/s13300-014-0067-x [doi]
AB  - Insulin degludec/insulin aspart (IDegAsp) is the first soluble co-formulation 
      which combines two insulin analogues, and provides effective basal and prandial 
      glycemic coverage. It has been assessed as basal insulin in type 2 diabetes 
      mellitus (T2DM), and as part of basal-bolus regime in both type 1 diabetes 
      mellitus and T2DM. Insulin degludec has also been assessed as flexibly 
      administered basal insulin in terms of time of administration. This review 
      discusses data pertaining to the efficacy, safety, tolerability, and clinical 
      potential of IDegAsp. The discussion includes comparisons of IDegAsp with basal 
      as well as premixed insulin.
FAU - Kalra, Sanjay
AU  - Kalra S
AD  - Department of Endocrinology, Bharti Hospital and BRIDE, Karnal, 132001, Haryana, 
      India, brideknl@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20140515
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC4065296
EDAT- 2014/05/16 06:00
MHDA- 2014/05/16 06:01
PMCR- 2014/05/15
CRDT- 2014/05/16 06:00
PHST- 2013/12/17 00:00 [received]
PHST- 2014/05/16 06:00 [entrez]
PHST- 2014/05/16 06:00 [pubmed]
PHST- 2014/05/16 06:01 [medline]
PHST- 2014/05/15 00:00 [pmc-release]
AID - 67 [pii]
AID - 10.1007/s13300-014-0067-x [doi]
PST - ppublish
SO  - Diabetes Ther. 2014 Jun;5(1):65-72. doi: 10.1007/s13300-014-0067-x. Epub 2014 May 
      15.